Calidi Biotherapeutics

Calidi Biotherapeutics is a clinical-stage immuno-oncology company pioneering the development of targeted therapies that deliver genetic medicines to distal sites of disease. The company's proprietary technology uses allogeneic stem cells (neural stem cells and adipose-derived mesenchymal stem cells) as delivery vehicles for oncolytic viruses, effectively 'cloaking' them from the patient's immune system to ensure targeted tumor lysis and immune activation. Headquartered in San Diego, Calidi is advancing a pipeline of 'off-the-shelf' universal cell-based delivery platforms designed to protect, amplify, and potentiate oncolytic viruses. Their approach aims to overcome the limitations of first-generation oncolytic viruses, such as rapid immune clearance, by using stem cells to shield the viral payload and facilitate its delivery directly into the tumor microenvironment.